# The Cigna Group (CI) Stock Analysis: Strong Buy Ratings and Potential Upside of 17.62%

- Link: https://www.directorstalkinterviews.com/the-cigna-group-ci-stock-analysis-strong-buy-ratings-and-potential-upside-of-17-62/4121253130
- Published: 2026-06-08T10:13:30+01:00
- Author: Madison Wilson

The Cigna Group (NYSE: CI) is making waves in the healthcare sector, with a robust
market capitalization of $76.58 billion. As a stalwart in the healthcare plans industry,
Cigna’s strategic focus covers a broad spectrum of services, positioning it as a
key player in the U.S. market and beyond. With its recent rebranding from Cigna 
Corporation to The Cigna Group in February 2023, the company continues to solidify
its presence with a diversified portfolio.

Cigna’s current stock price of $289.48 places it within the higher range of its 
52-week spectrum, which spans from $244.41 to $334.39. This stability is underscored
by a negligible price change of 0.03%, signaling steady investor confidence. The
company’s valuation metrics paint a compelling picture for potential investors. 
Notably, the forward P/E ratio stands at an attractive 8.65, suggesting that the
stock is potentially undervalued compared to its earnings growth prospects.

Despite the lack of net income data, Cigna demonstrates resilience with a revenue
growth of 4.60%. The company’s earnings per share (EPS) of 113.71 and a return on
equity (ROE) of 16.27% reflect its efficiency in generating profits from shareholders’
equity. Further boosting investor appeal is Cigna’s free cash flow, which exceeds
$6.9 billion, providing a strong foundation for sustainable growth and shareholder
returns.

Dividend-seeking investors will find Cigna’s yield of 2.16% appealing, particularly
given its conservative payout ratio of 5.36%. This low payout ratio indicates ample
room for future dividend increases, aligning with the company’s growth trajectory.

Analyst ratings further illuminate Cigna’s investment potential. With 20 buy ratings
and 4 hold ratings, the consensus is overwhelmingly positive. The absence of sell
ratings boosts confidence among investors. Analysts have set a target price range
of $290.00 to $400.00, with an average target of $340.50, suggesting a potential
upside of 17.62% from the current price level.

Technical indicators provide additional insights into Cigna’s current market position.
With the stock trading above both its 50-day and 200-day moving averages, at $279.75
and $281.85 respectively, the momentum appears favorable. However, the relative 
strength index (RSI) of 71.21 suggests that the stock may be approaching overbought
territory, a factor worth monitoring for short-term investors.

Cigna’s operational excellence is anchored in its two segments: Evernorth Health
Services and Cigna Healthcare. Evernorth offers comprehensive pharmacy benefit management
and clinical programs, while Cigna Healthcare delivers integrated medical solutions
for a diverse clientele, including international health services. This dual-segment
strategy ensures a balanced approach to market demands and revenue streams.

Founded in 1792 and headquartered in Bloomfield, Connecticut, The Cigna Group’s 
long-standing history and evolving strategies make it a compelling consideration
for investors seeking stable growth and dividend income in the healthcare sector.
As market dynamics continue to evolve, Cigna’s robust financial health and strategic
initiatives position it well for future success.

Share on: